Ignite Creation Date:
2024-05-06 @ 7:04 PM
Last Modification Date:
2024-10-26 @ 2:59 PM
Study NCT ID:
NCT05882396
Status:
NOT_YET_RECRUITING
Last Update Posted:
2023-05-31
First Post:
2023-05-19
Brief Title:
Roods Approach and Oxaliplatin-induced Peripheral Neuropathy in Colorectal Cancer Patients
Sponsor:
Cairo University
Organization:
Cairo University
Study Overview
Official Title:
Efficacy of Roods Approach on Oxaliplatin-induced Peripheral Neuropathy in Colorectal Cancer Patients
Status:
NOT_YET_RECRUITING
Status Verified Date:
2023-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Oxaliplatin-induced chronic peripheral neuropathy is of major concern to oncologists and patients as it has been shown to affect patients health-related quality of life Although a number of interventions have been implicated none of them can be recommended for clinical use This therapeutic failure reflects a poor understanding of the real mechanism of oxaliplatin-induced neuropathy However oxidative stress is identified to be one of the main biomolecular dysfunctions in this neuropathy Roods approach is a neurophysiological approach that is based on reflexes of the central nervous system in which the sensory stimulation provides desired muscular response and was specially designed for patients with motor control problems It was developed by Margeret Rood in 1940 According to Rood sensory stimulation can activate or deactivate the receptor by facilitation or inhibition which makes it possible to get the desired muscular response
Detailed Description:
So the purpose of the study is to investigate the efficiency of Roods approach on oxaliplatin-induced peripheral neuropathy in colorectal cancer patients
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None